X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration is focused on advancing the clinical development of the lead product candidate PrimeC (ciprofloxacin and celecoxib), which is currently undergoing mid-stage clinical trials for treating Alzheimer's disease.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Genetika
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 22, 2024
Details:
Lonza will develop, optimize, and qualify a method utilizing Neuron-Derived Exosomes, set to be integrated into the development program of PrimeC, a novel extended-release oral formulation of a unique fixed-dose combination of ciprofloxacin and celecoxib, by NeuroSense.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lonza Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 09, 2024
Details:
PrimeC is a novel extended-release oral formulation composed of a unique FDC of ciprofloxacin and celecoxib. It is under phase 2 clinical development for the treatment of amyotrophic lateral sclerosis (ALS).
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2024
Details:
PrimeC is a novel extended-release oral formulation composed of a unique FDC of ciprofloxacin and celecoxib. It is under phase 2 clinical development for the treatment of amyotrophic lateral sclerosis (ALS).
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
PrimeC (ciprofloxacin and celecoxib) is designed to synergistically target several key mechanisms of ALS that contribute to motor neuron degeneration, inflammation, iron accumulation and impaired RNA regulation to potentially inhibit the progression of ALS.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
PrimeC (ciprofloxacin and celecoxib) is designed to synergistically target several key mechanisms of ALS that contribute to motor neuron degeneration, inflammation, iron accumulation and impaired RNA regulation to potentially inhibit the progression of ALS.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
NeuroSense terminated the offering as the company is fully funded beyond clinical phase 2b ALS results of PrimeC, a unique formulation of a fixed-dose combination drug comprising ciprofloxacin and celecoxib, for amyotrophic lateral sclerosis.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering October 02, 2023
Details:
The net proceeds will advance the clinical development of PrimeC (ciprofloxacin) for amyotrophic lateral sclerosis and for the clinical development potential investigational new drug applications for Alzheimer's disease, for Parkinson's disease and for other indications.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $4.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 22, 2023
Details:
Under the terms of the agreement, Biogen will evaluate the impact of PrimeC (ciprofloxacin) and celecoxib on neurofilament levels in the plasma of participants in PARADIGM, NeuroSense’s Phase 2b clinical trial for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Biogen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 14, 2023
Details:
PrimeC (ciprofloxacin and celecoxib) is designed to synergistically target several key mechanisms of ALS that contribute to motor neuron degeneration, inflammation, iron accumulation and impaired RNA regulation to potentially inhibit the progression of ALS.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
